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a b s t r a c t
Myelodysplastic syndromes with myeloﬁbrosis (MDS-F) is a poor prognostic hematopoietic disorder.
Azacitidine was shown to prolong survival of high-risk MDS patients. However, the effects of azacitidine
on MDS-F have yet to be elucidated. Azacitidine was administered to a 74-year-old man with MDS-F at a
dose of 75 mg/m2/daily subcutaneously for 7 days every 28 days. Hematologic improvements were
observed according to the International Working Group 2006 criteria after 8 cycles of the azacitidine
treatment, and complete remission was achieved after 14 cycles. The grade of myeloﬁbrosis was also
improved. The therapeutic activity of azacitidine was conﬁrmed in our MDS-F patient.
& 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Myelodysplastic syndromes (MDS) are clonal hematopoietic dis-
orders characterized by ineffective hematopoiesis and potential trans-
formation to acute myeloid leukemia. The mainstay for the treatment
of MDS for decades was supportive care. However, supportive care
does not alter the natural course of MDS. The only curative treatment
for MDS is allogeneic stem cell transplantation (SCT).
Epigenetic changes play an important role in the pathogenesis of
myeloid neoplasms. Hence, the role of DNA methyltransferase
inhibitors such as azacitidine in achieving promising outcomes for
patients with MDS has been investigated. Azacitidine was shown to
signiﬁcantly prolong the survival of high-risk MDS patients [1].
However, the characteristics of MDS are very heterogeneous. Sig-
niﬁcant degrees of myeloﬁbrosis have been reported in approxi-
mately 10% of MDS patients. Myeloﬁbrosis was previously shown to
be a poor prognostic factor in MDS. The overall survival (OS) achieved
with allogeneic SCT was shown to be shorter in MDS patients with
severe myeloﬁbrosis than that in those without myeloﬁbrosis [2].
Azacitidine has been shown to have limited therapeutic activity in
patients with primary myeloﬁbrosis and post-essential thrombo-
cythemia (ET) / polycythemia vera (PV) myeloﬁbrosis [3]. Thalido-
mide, lenalidomide, and pomalidomide have also been shown to
exhibit the therapeutic activity in patients with myeloﬁbrosis with
myeloid metaplasia, primary myeloﬁbrosis, or post-ET / PV myeloﬁ-
brosis [4–6]. Previous studies suggested that the etiology of primary
myeloﬁbrosis may be associated with the activation of Janus kinase
(JAK)-signal transducer and activator of transcription (STAT) signaling
[7] and an increase in inﬂammatory cytokine levels [8]. Ruxolitinib, a
potent JAK1 and 2 inhibitor, has demonstrated reductions in spleno-
megaly and disease-related symptoms, and an improvement in
overall survival in patients with myeloﬁbrosis [9]. Myeloﬁbrosis with
MDS may also be associated with the activation of JAK–STAT
signaling and an increase in cytokine levels.
However, the effects of azacitidine on MDS with myeloﬁbrosis
(MDS-F) remain unknown. We here reported the successful
response of a MDS-F patient treated with azacitidine.
2. Case report
A 74-year-old man was transferred to our hospital with cytope-
nia. An initial peripheral blood examination revealed anemia:
hemoglobin (Hb) 9.5 g/dL, platelets (Plt) 71109/L, and white blood
cells (WBC) 1.84109/L with 0% blasts, 10% band forms, 23%
segmented neutrophils, 2% monocytes, and 65% lymphocytes. His
ferritin serum level was 197 ng/mL (30–310).
Bone marrow biopsy showed hyperplastic bone marrow with
myeloﬁbrosis and an increased number of megakaryocytes
(Fig. 1A). Differential counts were 29.0% erythroblasts, 10.3%
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myeloblasts, 2.3% promyelocytes, 7.0% myelocytes, 1.7% metamye-
locytes, 8.6% band forms, 10.5% segmented neutrophils, 1.3%
monocytes, 1.6% eosinophils, 0.6% basophils, and 25.9% lympho-
cytes. Blast cells in his bone marrow stained positive for myelo-
peroxidase and, based on an immunohistochemical analysis, were
also found to express CD34. Dysplasia was observed in tri-lineage
cells, and was severe in megakaryocytes and mild in neutrophils
and erythroblasts (Fig. 1B and C). A cytogenetic examination of
bone marrow cells by G-banding analysis showed the normal
karyotype, 46,XY[20/20]. The JAK2-V617F mutation was not
detected. He was diagnosed as refractory anemia with an excess
of blasts (RAEB)-2 with myeloﬁbrosis according to the 2008 World
Health Organization (WHO) classiﬁcation. The risk group was
classiﬁed as intermediate-2 in the International Prognostic Scoring
System (IPSS), high in the revised IPSS, and high in the WHO
classiﬁcation-based prognostic scoring system (WPSS). This mye-
loﬁbrosis was assessed as grade 3 following the European con-
sensus guidelines. Allogeneic SCT was judged to be an unsuitable
treatment because of his age and complications (type 2 diabetes
mellitus, and angina pectoris). Therefore, he was treated with
azacitidine. He required a red blood cell transfusion before being
treated with azacitidine. The risk group was classiﬁed as low in the
prognostic score for the azacitidine treatment [10].
Azacitidine was administered at a dose of 75 mg/m2/daily
subcutaneously for 7 consecutive days every 28 days. Transient
neutropenia was observed until the seventh cycle of the azaciti-
dine treatment was completed. A gradual increase in his blood cell
count was noted and the patient eventually became transfusion
independent. Hematological responses after 8 cycles of the azaci-
tidine treatment were considered to be hematologic improve-
ments, with erythroid (HI-E) and platelet (HI-P) responses
according to the International Working Group (IWG) 2006 criteria
(Table 1). A reduction in myeloﬁbrosis occurred after 4 cycles and
repeated bone marrow biopsies revealed a signiﬁcant improve-
ment in the grade of myeloﬁbrosis (Fig. 1D). The percentage of
myeloblasts after 8 cycles was 4.5%. However, the absolute
neutrophil count (ANC) was less than 1.0109/L. The efﬁcacy of
the azacitidine treatment was judged to be marrow complete
remission (marrow CR) with HI-E and HI-P responses. The ANC
increased gradually and exceeded 1.0109/L. CR was obtained
after 14 cycles of the azacitidine treatment (Table 1). A total of 20
cycles of this treatment have been completed to date. Hyperplastic
bone marrow with mild myeloﬁbrosis, an increased number of
megakaryocytes, and tri-lineage dysplasia with severe dysmega-
karyopoiesis still remains (Fig. 1E). Hematologic improvements
have been ongoing for 12 months, during which time 12 cycles of
the azacitidine treatment have been completed (Table 1).
3. Discussion
The pathogenesis of myeloﬁbrosis in MDS patients is unknown.
Clinical trials on azacitidine demonstrated the signiﬁcant and
clinically meaningful prolongation of OS in high-risk MDS patients
Fig. 1. A. Bone marrow biopsy before azacitidine treatment. Left: hyperplastic marrowwith myeloid hyperplasia and an increased number of megakaryocytes (Hematoxylin–
Eosin stain200). Right: dense reticulin ﬁbers with bundles of collagen. The grade of myeloﬁbrosis was assessed as grade 3 (Gomori's silver impregnation technique200).
B. Bone marrow aspirate smear before the azacitidine treatment (May–Giemsa stain1000). Left: myeloblasts. Center: hyposegmented mature neutrophils. Right: mild
megaloblastic changes in erythroblasts. C. Bone marrow biopsy before the azacitidine treatment (Hematoxylin–Eosin stain1000). Multinucleated and hypolobated nuclei
megakaryocytes. D. Bone marrow biopsy after the azacitidine treatment (Gomori's silver impregnation technique200). Left: after 4 cycles of the azacitidine treatment,
reticulin ﬁbers with focal bundles of collagen were assessed as grade 2. Right: after 8 cycles, a loose meshwork of thin reticulin ﬁbers was observed with grade
1 myeloﬁbrosis. E. Bone marrow aspirate smear after 20 cycles of the azacitidine treatment (May–Giemsa stain1000). Multinucleated and hypolobated nuclei
megakaryocytes, hyposegmented mature neutrophils, and mild megaloblastic changes in erythroblasts.
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[1]. However, the successful response of MDS-F patients to the
azacitidine treatment has not yet been reported.
Although thalidomide was previously shown to have anti-ﬁbrotic
effects in a MDS-F patient [11], suitable therapeutic agents for MDS-
F patients have not yet been established. Allogeneic SCT is currently
the only curative treatment for MDS patients with/without myeloﬁ-
brosis. The grade of myeloﬁbrosis is known to affect the engraftment
of allogeneic SCT in MDS patients; however, only severe myeloﬁ-
brosis has been shown to inﬂuence survival due to the higher risk of
relapse [2]. We showed that azacitidine exhibited therapeutic
activity in our MDS-F patient. If the severity of myeloﬁbrosis can
be reduced by azacitidine, this treatment may lead to signiﬁcant
prolongation of OS after allogeneic SCT in MDS-F patients.
Epigenetic changes play an important role in the pathogenesis
of myeloid neoplasms. Decitabine was previously shown to be
effective in an idiopathic myeloﬁbrosis patient [12]. However, the
pathogenesis of myeloﬁbrosis in ET / PV patients remains unclear.
A previous study that evaluated the activity of azacitidine in
patients with myeloﬁbrosis (primary and post-ET / PV) reported
that 19 (70%) of 27 patients had the JAK2 (V617F) mutation [3].
Responses included limited clinical improvements in 7 (21%)
patients and a partial response in only 1 (3%) patient. These
ﬁndings indicated that azacitidine exhibited limited therapeutic
activity for myeloﬁbrosis in patients with myeloproliferative
neoplasms such as primary and post-ET / PV myeloﬁbrosis.
Whereas, ruxolitinib, a potent and selective JAK1 and 2 inhibitor, as
compared with the best available therapy, in patients with myeloﬁ-
brosis (primary and post-ET / PV) has demonstrated rapid reductions
in splenomegaly, marked improvement in myeloﬁbrosis-associated
symptoms, and the prolongation of overall survival regardless of their
status with respect to the JAK2 (V617F) mutation [9]. JAK1 and
2 inhibitor therapy was considered for our patient with myeloﬁbrosis
if azacitidine treatment was not successful.
Our patient did not have myeloproliferative neoplasms such as
splenomegaly or the JAK2 (V617F) mutation. Therefore, he was
diagnosed with MDS-F, and achieved CR with reduced myeloﬁbrosis
with the azacitidine treatment. These ﬁndings indicate that azaciti-
dine may affect an MDS clone and indirectly improve myeloﬁbrosis.
This is the ﬁrst case of MDS-F that was successfully treated
with azacitidine. Our patient had RAEB-2 with myeloﬁbrosis
without the JAK2 (V617F) mutation. Severe dysplasia was observed
in his megakaryocytes. The grade of myeloﬁbrosis was improved
and CR was obtained after the long-term treatment with azaciti-
dine; however, tri-lineage dysplasia remains. The delay observed
in hematologic improvements in our patient may be attributed to
severe myeloﬁbrosis. Therefore, these results indicate that a
subsequent and long-term treatment with azacitidine may be
required to obtain hematologic improvements and reduce myelo-
ﬁbrosis in patients with MDS-F.
A large scale study is needed to clarify the relationship between
anti-ﬁbrotic effects and treatment with azacitidine in MDS-F patients.
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